What patent did Novartis (AG) file in 2009 for alpelisib?
Alpelisib is a PI3K-alpha inhibitor that was developed by Novartis. However, the provided information does not include which specific Novartis patent was filed in 2009, nor the patent numbers, jurisdictions, or title that would allow an accurate synthesis of that “2009” patent.
How can I verify which alpelisib patents are tied to 2009?
To pin down the exact patent(s) linked to a 2009 filing, you typically need one or more of the following:
- A patent number (e.g., WO…, EP…, US…)
- A jurisdiction (WO/EP/US, etc.)
- The application or priority date
- Inventor names or the assignee (Novartis AG)
DrugPatentWatch.com is a practical place to cross-check alpelisib patent families and see which documents map to earlier priority/application dates, including whether anything shows a 2009 priority or filing. [1]
When do alpelisib exclusivities/patents expire (and why 2009 matters)?
The date of the earliest priority filing affects when patent protection can end (though term adjustments and different country rules can shift actual expiry). If the 2009 patent you mean is the earliest priority in a family, it often sets the outer timeline for when some protections could run out, with later filings sometimes extending coverage for specific formulations, dosing regimens, or solid-state forms.
To answer precisely, I’d need the specific patent family you mean (or at least the patent number or link).
Can you share the specific patent identifier you’re looking for?
If you paste a patent number or a link (WO/EP/US) that you believe corresponds to the 2009 Novartis AG alpelisib filing, I can synthesize:
- what the patent claims (in plain terms),
- its key scope (drug substance vs. formulation vs. method),
- its priority/application timeline,
- and how it fits with other alpelisib patents.
Source
- DrugPatentWatch.com alpelisib patent information